ESO-EANO Masterclass in Neuro-Oncology: Challenges in Radiotherapy for Patients with Gliomas

Chairs: M. Brada, UK - E. Moyal, FR
Host Chair: G. Pesce, CH

The Masterclass offers plenary lectures on the state-of-the-art clinical evaluation and treatments with reference to clinical guidelines concluding with take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the faculty. Contouring sessions will give the participants the opportunity to experience challenging situations in the treatment of gliomas and to exchange ideas with the experts about the controversies in the management of difficult cases encountered in the daily radiotherapy practice.


LEARNING OBJECTIVES
• Improve clinical oncologists’ skills
• Practising case discussion
• Improve the confidence while prescribing radiotherapy and using modern radiotherapy equipment and planning systems (IMRT, stereotactic radiotherapy, protons, etc.)
• Focus on clinical aspects of patients with gliomas, radiobiology, pathology and molecular biology of gliomas from radiation oncology perspective
• Compact update on epidemiology, combination of radiotherapy with surgery and drug therapy and clinical trials


MAIN TOPICS
• Clinical management of patients with gliomas
• Radiobiology of gliomas
• Technical improvements, altered fractionation, aspects of high precision radiotherapy, chemosensitization and other aspects of medical therapy
• Treatment of low grade gliomas, glioblastoma, anaplastic astrocytomas and oligodendrogliomas, rare brain tumors, pediatric brain tumors in adults
• Supportive treatments, symptom control both with palliative and curative intent


TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and will conclude in take-home messages. The clinical sessions will be complemented by tumor board discussions supported by the chairs.
Participants will be encouraged to deliver case presentations within small groups and discuss these with the chairs and the faculty.
All participants will reside at the course venue and participation will be expected to be present throughout the course.
The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.


THE MASTERCLASS IS
• A 3-day residential educational event
• Full immersion
• Clinically-oriented
• Multidisciplinary
• Delivered by an international faculty of experts

Held in cooperation with

Endorsed by

ORGANISING SECRETARIAT
European School of Oncology
Piazza Indipendenza 2
6500 Bellinzona
Switzerland  

Participants and organisation:
Luis Carvalho - ph +41 91 820 0958 - lcarvalho@eso.net

Programme secretariat:
Laura Richetti - ph +41 91 820 0951 - lrichetti@eso.net


VENUE
Hotel de la Paix
Via Cattori 18
6900 Lugano
Switzerland


CME ACCREDITATION AND CERTIFICATES
Participants will be entitled to receive a certificate of attendance at the close of the Masterclass by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.
The event is designated for a maximum of 14 European CME credits (ECMEC).
Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.


ACKNOWLEDGEMENT
ESO wishes to express its gratefulness to Varian for having provided the working stations supporting the contouring sessions during the event.

FACULTY
C.N. Azinwi, Oncology Institute of Southern Switzerland, Lugano, CH
B. Baumert, MediClin Robert-Janker Clinic, Bonn, DE
L. Bertero, University of Turin, IT
G. Bianchi Micheli, Senology Unit of Southern Switzerland, Lugano, CH
M. Brada, University of Liverpool and Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Wirral, UK
A. Cianfoni, Neurocenter of Southern Switzerland, Lugano, CH
P. Colleoni, Medical Physics Service EOC, Bellinzona, CH
S. Combs, Munich Technical University – Klinikum rechts der Isar der Technischen Universität Munchen, Munich, DE
F. Dhermain, Institut Gustave Roussy, Villejuif, FR
M. Frattini, Cantonal Institute of Pathology, Locarno, CH
C. Gamondi, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Hottinger, Lausanne University Hospital, Lausanne, CH
A. Kaelin, Neurocenter of Southern Switzerland, Lugano, CH
J. Khalifa, Institute Universitaire du Cancer Toulouse Oncopole, Toulouse, FR
E. Le Rhun, Lille University Hospital, Lille, FR
E. Moyal, Institute Universitaire du Cancer Toulouse Oncopole, Toulouse, FR
G. Pesce, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Pica, Paul Scherrer Institute, Villingen, CH
S. Presilla, Medical Physics Service EOC, Bellinzona, CH
M. Reinert, Regional Hospital of Lugano, Neuocenter of Southern Switzerland, Lugano, CH
U. Roelcke, Aarau Cantonal Hospital, Aarau, CH
P. Roth, University Hospital Zurich, CH
R. Rudà, University Hospital of Turin, IT
R. Soffietti, University Hospital of Turin, IT
L. Zenone, Oncology Institute of Southern Switzerland, Bellinzona, CH
M. Weller, University Hospital Zurich, Zurich, CH
 

 15 September

 16 September

 17 September